GSK's Patrick Vallance, senior vice president of medicines discovery and development says GSK is not interested in buying Genzyme. He characterizes that type of big merger as destructive to the R&D effort due to all the distractions associated with integration. GSK would rather maintain a stable R&D environment while it pursues its current pipeline projects.
Vallance did say that GSK will continue to pursue its initiative in rare diseases. Small deals with biotech's will be considered and executed if they would help this effort to build a portfolio of treatments. GSK has previously indicated that it will shoot for 200 therapies. GSK believes it can make an impact in the rare disease area and avoid competition and price presssure seen in bigger therapeutic areas like depression or schizophrenia. See Fierce Biotech story.
Posted by Bruce Lehr November 19th 2010.